Myogenes included the ACKR1/Duffy-null genotype test in the NHS National Genomic Test Directory.
Public source
Publisher name
Public post
Day 8 (Finale): What We Are Asking For Seven days of evidence. One ask. Recognise genotype testing in national suicide prevention and mental health strategy — as an enab…
Company
Myogenes
Helping GPs and Psychiatrists choose the right medication for their patients. Psychiatric Testing | DNA Testing
- Industry
- Medical Practices
- Location
- Elstree, GB
- Company size
- 11–50 employees
About Myogenes
Helping GP's and Psychiatrists choose the right medication for their patients. Psychiatric Testing | DNA Testing | Cancer Testing | Pharmacogentic Testing
See moreLatest activity
Latest activity from Myogenes
5 signals
Strategy & Corporate Development
Myogenes commissioned a service evaluation across mental health trusts to assess clozapine access, initiation, discontinuation, and time to initiation, disaggregated by ethnicity.
Strategy & Corporate Development
Myogenes adopted the CERSI-PGx guideline into the national clozapine pathway.
Research & Knowledge
Myogenes published evidence showing that ACKR1/Duffy-null genotype testing in national suicide prevention and mental health strategy can be recognized as an enabler of timely clozapine access.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Synnovis
Synnovis was a key collaborative partner in the development and application of a revolutionary metagenomics test that identifies illness much faster by sequencing pathogen DNA from a single sample.
Products & Services
Yourgene Health
Yourgene Health launched Yourgene Insight DPYD to celebrate the project and invite participants to share reflections on the journey.
Research & Knowledge
Variantyx
Variantyx published a case study involving a 14-month-old patient presenting with profound global developmental delay and multiple congenital anomalies, including complex craniofacial features, cardiac defects, and skeletal abnormalities, who was tested with Variantyx Genomic Unity® and had negative results after a year of rapid whole genome trio testing in the NICU.
Products & Services
Atila Biosystems
Atila Biosystems launched a new panel of PGx panels using RT-PCR technology to identify variants across 35 pharmacogenes with 6 preset panels
Research & Knowledge
Rare Medical Network